Usefulness of HATCH score in the prediction of new-onset atrial fibrillation for Asians

Kazuyoshi Suenari, Tze-Fan Chao, Chia-Jen Liu, Yasuki Kihara, Tzeng-Ji Chen, Shih-Ann Chen, Kazuyoshi Suenari, Tze-Fan Chao, Chia-Jen Liu, Yasuki Kihara, Tzeng-Ji Chen, Shih-Ann Chen

Abstract

The HATCH score (hypertension <1 point>, age >75 years <1 point>, stroke or transient ischemic attack <2 points>, chronic obstructive pulmonary disease <1 point>, and heart failure <2 points>) was reported to be useful for predicting the progression of atrial fibrillation (AF) from paroxysmal to persistent or permanent AF for patients who participated in the Euro Heart Survey. The goal of the current study was to investigate whether the HATCH score was a useful scheme in predicting new-onset AF. Furthermore, we aimed to use the HATCH scoring system to estimate the individual risk in developing AF for patients with different comorbidities. We used the "Taiwan National Health Insurance Research Database." From January 1, 2000, to December 31, 2001, a total of 670,804 patients older than 20 years old and who had no history of cardiac arrhythmias were enrolled. According to the calculation rule of the HATCH score, 599,780 (score 0), 46,661 (score 1), 12,892 (score 2), 7456 (score 3), 2944 (score 4), 802 (score 5), 202 (score 6), and 67 (score 7) patients were studied and followed for the new onset of AF. During a follow-up of 9.0 ± 2.2 years, there were 9174 (1.4%) patients experiencing new-onset AF. The incidence of AF was 1.5 per 1000 patient-years. The incidence increased from 0.8 per 1000 patient-years for patients with a HATCH score of 0 to 57.3 per 1000 patient-years for those with a HATCH score of 7. After an adjustment for the gender and comorbidities, the hazard ratio (95% confidence interval) of each increment of the HATCH score in predicting AF was 2.059 (2.027-2.093; P < 0.001). The HATCH score was useful in risk estimation and stratification of new-onset AF.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
The flowchart of the enrollment of the study patients.
Figure 2
Figure 2
Incidence of new-onset AF in patients with different HATCH scores. AF = atrial fibrillation.
Figure 3
Figure 3
The cumulative incidence curves with a log-rank test demonstrated that patients with higher HATCH scores were associated with a higher rate of new-onset AF during the follow-up period. AF = atrial fibrillation.
Figure 4
Figure 4
Risk of new-onset AF in patients with different HATCH scores. AF = atrial fibrillation.

References

    1. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760–4.
    1. Takahashi N, Seki A, Imataka K, et al. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J 1981;22:143–9.
    1. de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725–31.
    1. Chang TY, Chao TF, Liu CJ, et al. The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study. Heart Rhythm 2016;13:1189–94.
    1. Chao TF, Liu CJ, Chen SJ, et al. CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan. Int J Cardiol 2013;168:1360–3.
    1. Chao TF, Liu CJ, Tuan TC, et al. Rate-control treatment and mortality in atrial fibrillation. Circulation 2015;132:1604–12.
    1. Chao TF, Liu CJ, Tuan TC, et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians? Heart Rhythm 2016;13:46–53.
    1. Chao TF, Liu CJ, Tuan TC, et al. Impact on outcomes of changing treatment guideline recommendations for stroke prevention in atrial fibrillation: a nationwide cohort study. Mayo Clin Proc 2016;91:567–74.
    1. Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ’low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol 2014;64:1658–65.
    1. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;65:635–42.
    1. Chao TF, Wang KL, Liu CJ, et al. Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan. J Am Coll Cardiol 2015;66:1339–47.
    1. Chao TF, Liu CJ, Liao JN, et al. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540–7.
    1. Lin CC, Lai MS, Syu CY, et al. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005;104:157–63.
    1. Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011;20:236–42.
    1. Chen SJ, Liu CJ, Chao TF, et al. Dental scaling and atrial fibrillation: a nationwide cohort study. Int J Cardiol 2013;168:2300–3.
    1. Lin LJ, Cheng MH, Lee CH, et al. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation—a nationwide descriptive study in Taiwan. Clin Ther 2008;30:1726–36.
    1. Chang CH, Lee YC, Tsai CT, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 2014;232:224–30.
    1. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659–66.
    1. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999;100:1879–86.
    1. Lin YJ, Suenari K, Lo MT, et al. Novel assessment of temporal variation in fractionated electrograms using histogram analysis of local fractionation interval in patients with persistent atrial fibrillation. Circ Arrhythm Electrophysiol 2012;5:949–56.
    1. Tuan TC, Chang SL, Tsao HM, et al. The impact of age on the electroanatomical characteristics and outcome of catheter ablation in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2010;21:966–72.
    1. Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 2010;106:1615–20.
    1. Dankner R, Goldbourt U, Boyko V, et al. Predictors of cardiac and noncardiac mortality among 14,697 patients with coronary heart disease. Am J Cardiol 2003;91:121–7.
    1. Sidney S, Sorel M, Quesenberry CP, Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068–75.
    1. Huang B, Yang Y, Zhu J, et al. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. J Am Med Dir Assoc 2014;15:576–81.
    1. Li J, Agarwal SK, Alonso A, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2014;129:971–80.
    1. Johnson LS, Juhlin T, Engstrom G, et al. Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace 2014;16:182–8.
    1. Ryu JH, Krowka MJ, Pellikka PA, et al. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 2007;82:342–50.
    1. Alonso A, Tang W, Agarwal SK, et al. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. Int J Cardiol 2012;155:217–22.
    1. Stevenson IH, Roberts-Thomson KC, Kistler PM, et al. Atrial electrophysiology is altered by acute hypercapnia but not hypoxemia: implications for promotion of atrial fibrillation in pulmonary disease and sleep apnea. Heart Rhythm 2010;7:1263–70.
    1. Ball J, Carrington MJ, McMurray JJ, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807–24.
    1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837–47.
    1. Tse HF, Wang YJ, Ahmed Ai-Abdullah M, et al. Stroke prevention in atrial fibrillation—an Asian stroke perspective. Heart Rhythm 2013;10:1082–8.
    1. Chamberlain AM, Agarwal SK, Folsom AR, et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011;107:85–91.
    1. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739–45.
    1. Rizzo MR, Sasso FC, Marfella R, et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications 2015;29:88–92.
    1. Marfella R, Sasso FC, Siniscalchi M, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol 2013;62:525–30.
    1. Sardu C, Santamaria M, Rizzo MR, et al. Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study. Int J Clin Pract 2016;70:569–76.
    1. Jansen JW, Haverkate F, Koopman J, et al. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thromb Haemost 1987;57:171–5.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner